Viriom

Industry · 17 registered clinical trials.

Status	Trial	Phase	Started
Completed	Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of HIV-1-infection	Phase 1	2022-04-12
Unknown	Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care HIV-1-infection	Phase 2 / Phase 3	2022-04-01
Unknown	Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza Influenza	Phase 3	2022-01-15
Completed	An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single Covid19, HIV-1-infection	Phase 1	2021-01-23
Completed	Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HI HIV-1-infection	Phase 1 / Phase 2	2021-01-19
Unknown	Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers HIV Infections	Phase 1	2019-05-01
Completed	Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Dose HIV-1-infection	Phase 1	2019-01-21
Completed	Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers HIV Infections	Phase 1	2018-12-18
Completed	Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Othe HIV-1-infection	Phase 1	2018-11-14
Completed	Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to HIV-1-infection, Hepatic Impairment	Phase 1	2018-10-01
Completed	Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrat HIV-1-infection	Phase 1	2018-06-01
Unknown	Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Backgr HIV-1-infection	—	2018-03-15
Completed	Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza Influenza	Phase 2	2017-11-13
Completed	Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500 HIV-infection	Phase 1	2014-09-01
Completed	Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretrovir HIV-1-infection	Phase 2 / Phase 3	2014-08-05
Completed	Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of HIV Infection	Phase 1 / Phase 2	2013-03-01
Completed	Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunte HIV-infection	Phase 1	2012-07-01